XDx blood test for heart-transplant rejection gets FDA clearance

08/27/2008 | FDAnews · Yahoo!

XDx has received FDA approval to market AlloMap, a blood test designed to help doctors monitor potential organ rejection in heart-transplant patients without the need for repeated biopsies. The test uses blood samples to analyze certain genetic information in white blood cells.

View Full Article in:

FDAnews · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care